Provensis suffers new US blow on Varisolve
This article was originally published in Clinica
BTG subsidiary Provensis suffered a major setback last week after failing to release its varicose veins treatment, Varisolve (polidocanol microfoam), from clinical hold in the US where it has been since November last year, due to the potential risks of gas embolism (see Clinica No 1073, p 15). News of the delay was accompanied by an announcement that Provensis would need to minimise operational costs, including cutting a number of the 39 staff working on the Varisolve project. BTG's share price fell 30% to 98p when the news was released.
You may also be interested in...
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.